Case-based review

Primary central nervous system lymphoma

Agnieszka Korfel, Uwe Schlegel, Derek R. Johnson, Timothy J Kaufmann, Caterina Giannini, Takanori Hirose

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Primary CNS lymphoma (PCNSL) is a rare diffuse large B-cell lymphoma originating within the central nervous system. The overall incidence of PCNSL is rising, particularly in the elderly population. Immunosuppression is a strong risk factor, but most patients with this tumor are apparently immunocompetent. Diagnosis of PCNSL can be challenging. Non-invasive or minimally invasive tests such as ophthalmological evaluation and spinal fluid analysis may be useful, but the majority of patients require tumor biopsy for definitive diagnosis. Our knowledge concerning optimum treatment of PCNSL is fragmentary due to paucity of adequately sized trials. Most patients are now initially treated with high-dose-methotrexate-based chemotherapy alone, as the addition of whole-brain radiotherapy at standard doses has not been shown to increase survival and does increase the risk of neurological toxicity. Ongoing trials are addressing issues such as the roles of reduced-dose radiotherapy, the addition of the CD20 antibody rituximab to chemotherapy, high-dose chemotherapy followed by autologous stem cell transplantation, and maintenance therapy in the primary management of PCNSL.

Original languageEnglish (US)
Pages (from-to)46-59
Number of pages14
JournalNeuro-Oncology Practice
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Lymphoma
Central Nervous System
Drug Therapy
Radiotherapy
Lymphoma, Large B-Cell, Diffuse
Stem Cell Transplantation
Methotrexate
Immunosuppression
Neoplasms
Biopsy
Survival
Incidence
Brain
Therapeutics
Population

Keywords

  • High-dose methotrexate
  • Neurotoxicity
  • Primary CNS lymphoma
  • Whole-brain radiotherapy

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Case-based review : Primary central nervous system lymphoma. / Korfel, Agnieszka; Schlegel, Uwe; Johnson, Derek R.; Kaufmann, Timothy J; Giannini, Caterina; Hirose, Takanori.

In: Neuro-Oncology Practice, Vol. 4, No. 1, 01.01.2017, p. 46-59.

Research output: Contribution to journalArticle

Korfel, Agnieszka ; Schlegel, Uwe ; Johnson, Derek R. ; Kaufmann, Timothy J ; Giannini, Caterina ; Hirose, Takanori. / Case-based review : Primary central nervous system lymphoma. In: Neuro-Oncology Practice. 2017 ; Vol. 4, No. 1. pp. 46-59.
@article{1a274c3b79ea4d9a84865ba393eaa600,
title = "Case-based review: Primary central nervous system lymphoma",
abstract = "Primary CNS lymphoma (PCNSL) is a rare diffuse large B-cell lymphoma originating within the central nervous system. The overall incidence of PCNSL is rising, particularly in the elderly population. Immunosuppression is a strong risk factor, but most patients with this tumor are apparently immunocompetent. Diagnosis of PCNSL can be challenging. Non-invasive or minimally invasive tests such as ophthalmological evaluation and spinal fluid analysis may be useful, but the majority of patients require tumor biopsy for definitive diagnosis. Our knowledge concerning optimum treatment of PCNSL is fragmentary due to paucity of adequately sized trials. Most patients are now initially treated with high-dose-methotrexate-based chemotherapy alone, as the addition of whole-brain radiotherapy at standard doses has not been shown to increase survival and does increase the risk of neurological toxicity. Ongoing trials are addressing issues such as the roles of reduced-dose radiotherapy, the addition of the CD20 antibody rituximab to chemotherapy, high-dose chemotherapy followed by autologous stem cell transplantation, and maintenance therapy in the primary management of PCNSL.",
keywords = "High-dose methotrexate, Neurotoxicity, Primary CNS lymphoma, Whole-brain radiotherapy",
author = "Agnieszka Korfel and Uwe Schlegel and Johnson, {Derek R.} and Kaufmann, {Timothy J} and Caterina Giannini and Takanori Hirose",
year = "2017",
month = "1",
day = "1",
doi = "10.1093/nop/npw033",
language = "English (US)",
volume = "4",
pages = "46--59",
journal = "Neuro-Oncology Practice",
issn = "2054-2577",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Case-based review

T2 - Primary central nervous system lymphoma

AU - Korfel, Agnieszka

AU - Schlegel, Uwe

AU - Johnson, Derek R.

AU - Kaufmann, Timothy J

AU - Giannini, Caterina

AU - Hirose, Takanori

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Primary CNS lymphoma (PCNSL) is a rare diffuse large B-cell lymphoma originating within the central nervous system. The overall incidence of PCNSL is rising, particularly in the elderly population. Immunosuppression is a strong risk factor, but most patients with this tumor are apparently immunocompetent. Diagnosis of PCNSL can be challenging. Non-invasive or minimally invasive tests such as ophthalmological evaluation and spinal fluid analysis may be useful, but the majority of patients require tumor biopsy for definitive diagnosis. Our knowledge concerning optimum treatment of PCNSL is fragmentary due to paucity of adequately sized trials. Most patients are now initially treated with high-dose-methotrexate-based chemotherapy alone, as the addition of whole-brain radiotherapy at standard doses has not been shown to increase survival and does increase the risk of neurological toxicity. Ongoing trials are addressing issues such as the roles of reduced-dose radiotherapy, the addition of the CD20 antibody rituximab to chemotherapy, high-dose chemotherapy followed by autologous stem cell transplantation, and maintenance therapy in the primary management of PCNSL.

AB - Primary CNS lymphoma (PCNSL) is a rare diffuse large B-cell lymphoma originating within the central nervous system. The overall incidence of PCNSL is rising, particularly in the elderly population. Immunosuppression is a strong risk factor, but most patients with this tumor are apparently immunocompetent. Diagnosis of PCNSL can be challenging. Non-invasive or minimally invasive tests such as ophthalmological evaluation and spinal fluid analysis may be useful, but the majority of patients require tumor biopsy for definitive diagnosis. Our knowledge concerning optimum treatment of PCNSL is fragmentary due to paucity of adequately sized trials. Most patients are now initially treated with high-dose-methotrexate-based chemotherapy alone, as the addition of whole-brain radiotherapy at standard doses has not been shown to increase survival and does increase the risk of neurological toxicity. Ongoing trials are addressing issues such as the roles of reduced-dose radiotherapy, the addition of the CD20 antibody rituximab to chemotherapy, high-dose chemotherapy followed by autologous stem cell transplantation, and maintenance therapy in the primary management of PCNSL.

KW - High-dose methotrexate

KW - Neurotoxicity

KW - Primary CNS lymphoma

KW - Whole-brain radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85047053420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047053420&partnerID=8YFLogxK

U2 - 10.1093/nop/npw033

DO - 10.1093/nop/npw033

M3 - Article

VL - 4

SP - 46

EP - 59

JO - Neuro-Oncology Practice

JF - Neuro-Oncology Practice

SN - 2054-2577

IS - 1

ER -